Skip to main content

Table 1 Characteristics of patients with metastatic thyroid cancer to the lung treated with TKI by cavitation status

From: Pulmonary cavitation in patients with thyroid cancer receiving antiangiogenic agents

Covariate Entire cohort (N = 83,%) Cavitation
(N = 10,%)
No cavitation (N = 73,%) P-value
Male, no. 39 (47%) 4 (40%) 35 (47.9) 0.637
Age, mean ± standard deviation 60.9 ± 13.4 years 64.9 ± 6.5 years 60.39 ± 14.0 years 0.317
Race/ethnicity, no. 0.313
 White 50 (60%) 5 (50%) 45 (61.6%)
 Black 8 (9.6%) 0 (0.0%) 8 (11%)
 Hispanic 17 (20.5%) 3 (30%) 14 (19%)
 Asian 7 (8.4%) 2 (20%) 5 (6.8%)
Cancer type, no. 0.068
 Papillary 39 (47%) 7 (70%) 32 (43.8%)
 Follicular 6 (7.2%) 2 (20%) 4 (5.4%)
 Poorly differentiated/anaplastic 26 (31.3%) 1 (10%) 25 (34.2%)
 Other 12 (14.4%) 0 (0.0%) 12 (16.4%)
Pleural base lesions on imaging, no. 15 (18%) 4 (40%) 11 (15%) 0.055
Emphysema on imaging, no. 6 (7.2%) 0 (0.0%) 6 (8.2%) 0.347
Prior radiation to the chest, no. 2 (2.4%) 0 (0.0%) 2 (2.7%) 0.596
Drug used, no. 0.579
 Lenvatinib 68 (82%) 7 (70%) 61 (83.5%)
 Sorafenib and lenvatinib 10 (12%) 2 (20%) 8 (11%)
 Other 5 (6%) 1 (10%) 4 (5.4%)
Lung metastasis responded to TKI, no. 37 (44.5%) 6 (60%) 31 (42.4%) 0.295
  1. TKI tyrosine kinase inhibitor
\